VanEck Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.6M | Sell |
1,621,481
-23,668
| -1% | -$1.12M | 0.04% | 248 |
|
|
2025
Q4 | $83.7M | Buy |
1,645,149
+856,427
| +109% | +$43.8M | 0.07% | 175 |
|
|
2025
Q3 | $43.8M | Buy |
788,722
+120,127
| +18% | +$7.03M | 0.04% | 234 |
|
|
2025
Q2 | $46.1M | Buy |
668,595
+221,038
| +49% | +$15M | 0.05% | 216 |
|
|
2025
Q1 | $31.1M | Sell |
447,557
-15,428
| -3% | -$1.27M | 0.04% | 252 |
|
|
2024
Q4 | $39.8M | Sell |
462,985
-29,482
| -6% | -$3.19M | 0.05% | 206 |
|
|
2024
Q3 | $57M | Buy |
492,467
+64,635
| +15% | +$8.62M | 0.07% | 168 |
|
|
2024
Q2 | $61.1M | Buy |
427,832
+19,931
| +5% | +$2.64M | 0.09% | 152 |
|
|
2024
Q1 | $52.4M | Buy |
407,901
+83,164
| +26% | +$9.9M | 0.08% | 157 |
|
|
2023
Q4 | $33.6M | Buy |
324,737
+51,451
| +19% | +$5.09M | 0.06% | 183 |
|
|
2023
Q3 | $24.9M | Buy |
273,286
+34,224
| +14% | +$3.01M | 0.05% | 204 |
|
|
2023
Q2 | $19.3M | Sell |
239,062
-48,666
| -17% | -$3.98M | 0.04% | 246 |
|
|
2023
Q1 | $22.9M | Sell |
287,728
-177,596
| -38% | -$12.6M | 0.05% | 223 |
|
|
2022
Q4 | $31.5M | Sell |
465,324
-60,054
| -11% | -$3.52M | 0.08% | 186 |
|
|
2022
Q3 | $26.2M | Buy |
525,378
+8,318
| +2% | +$446K | 0.08% | 192 |
|
|
2022
Q2 | $28.8M | Buy |
517,060
+175,086
| +51% | +$9.72M | 0.08% | 204 |
|
|
2022
Q1 | $19M | Buy |
341,974
+29,678
| +10% | +$1.52M | 0.04% | 260 |
|
|
2021
Q4 | $17.5M | Sell |
312,296
-17,776
| -5% | -$963K | 0.04% | 276 |
|
|
2021
Q3 | $15.8M | Buy |
330,072
+47,032
| +17% | +$2.27M | 0.04% | 281 |
|
|
2021
Q2 | $11.9M | Sell |
283,040
-40,002
| -12% | -$1.55M | 0.03% | 320 |
|
|
2021
Q1 | $10.9M | Sell |
323,042
-35,510
| -10% | -$1.26M | 0.03% | 326 |
|
|
2020
Q4 | $12.5M | Buy |
358,552
+4,066
| +1% | +$141K | 0.04% | 273 |
|
|
2020
Q3 | $12.3M | Buy |
354,486
+35,464
| +11% | +$1.18M | 0.04% | 236 |
|
|
2020
Q2 | $10.4M | Sell |
319,022
-2,320
| -0.7% | -$74K | 0.04% | 250 |
|
|
2020
Q1 | $9.67M | Sell |
321,342
-26,228
| -8% | -$781K | 0.05% | 218 |
|
|
2019
Q4 | $10.1M | Buy |
347,570
+63,904
| +23% | +$1.77M | 0.04% | 258 |
|
|
2019
Q3 | $7.33M | Sell |
283,666
-43,818
| -13% | -$1.11M | 0.03% | 270 |
|
|
2019
Q2 | $8.36M | Sell |
327,484
-51,330
| -14% | -$1.27M | 0.04% | 250 |
|
|
2019
Q1 | $9.91M | Sell |
378,814
-163,018
| -30% | -$4.01M | 0.05% | 217 |
|
|
2018
Q4 | $12.5M | Sell |
541,832
-8,818
| -2% | -$196K | 0.06% | 207 |
|
|
2018
Q3 | $13M | Sell |
550,650
-45,458
| -8% | -$1.11M | 0.06% | 221 |
|
|
2018
Q2 | $13.7M | Buy |
596,108
+101,554
| +21% | +$2.41M | 0.06% | 210 |
|
|
2018
Q1 | $12.2M | Sell |
494,554
-21,970
| -4% | -$577K | 0.06% | 221 |
|
|
2017
Q4 | $13.9M | Sell |
516,524
-57,822
| -10% | -$1.47M | 0.07% | 206 |
|
|
2017
Q3 | $13.8M | Sell |
574,346
-67,444
| -11% | -$1.52M | 0.07% | 216 |
|
|
2017
Q2 | $13.8M | Sell |
641,790
-266,308
| -29% | -$5.37M | 0.08% | 201 |
|
|
2017
Q1 | $15.6M | Buy |
908,098
+247,904
| +38% | +$4.32M | 0.07% | 188 |
|
|
2016
Q4 | $11.8M | Buy |
660,194
+138,760
| +27% | +$2.52M | 0.06% | 199 |
|
|
2016
Q3 | $10.8M | Buy |
521,434
+59,526
| +13% | +$1.48M | 0.05% | 202 |
|
|
2016
Q2 | $12.4M | Sell |
461,908
-3,850
| -0.8% | -$106K | 0.06% | 182 |
|
|
2016
Q1 | $12.6M | Sell |
465,758
-173,078
| -27% | -$4.64M | 0.09% | 155 |
|
|
2015
Q4 | $18.6M | Buy |
638,836
+41,724
| +7% | +$1.15M | 0.15% | 137 |
|
|
2015
Q3 | $16.2M | Sell |
597,112
-72,194
| -11% | -$2.04M | 0.12% | 139 |
|
|
2015
Q2 | $18.3M | Sell |
669,306
-40,488
| -6% | -$1.14M | 0.11% | 155 |
|
|
2015
Q1 | $18.9M | Sell |
709,794
-5,084
| -0.7% | -$117K | 0.11% | 151 |
|
|
2014
Q4 | $15.1M | Sell |
714,878
-158,508
| -18% | -$3.54M | 0.09% | 165 |
|
|
2014
Q3 | $20.8M | Buy |
873,386
+115,198
| +15% | +$2.65M | 0.11% | 143 |
|
|
2014
Q2 | $17.5M | Buy |
758,188
+72,620
| +11% | +$1.6M | 0.08% | 155 |
|
|
2014
Q1 | $15.6M | Buy |
685,568
+43,218
| +7% | +$921K | 0.08% | 155 |
|
|
2013
Q4 | $11.9M | Sell |
642,350
-5,870
| -0.9% | -$102K | 0.06% | 173 |
|
|
2013
Q3 | $11M | Buy |
648,220
+2,480
| +0.4% | +$41.7K | 0.06% | 166 |
|
|
2013
Q2 | $10M | Buy |
+645,740
| New | +$10.7M | 0.05% | 169 |
|
Other funds holding NVO
DAM
F
VanEck Associates's NVO Position: Q1 2026 in Review
VanEck Associates reduced its Novo Nordisk (NVO) stake by 1.4% in Q1 2026, selling an estimated $1.12M and leaving 1,621,481 shares worth $59.6M. The position accounts for 0.04% of the portfolio, ranked #248.
VanEck Associates first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $83.7M in Q4 2025. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- VanEck Associates held 1,621,481 shares of Novo Nordisk worth $59.6M as of Q1 2026.
- VanEck Associates sold 23,668 Novo Nordisk shares in Q1 2026, an estimated $1.12M.
- Novo Nordisk made up 0.04% of VanEck Associates's portfolio in Q1 2026, its #248 holding.
- VanEck Associates first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
- VanEck Associates's Novo Nordisk position peaked at $83.7M in Q4 2025.
- 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.